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Introduction: Peripartum Cardiomyopathy (PPCM) is defined on the basis of 4 
criteria:  
 The development of cardiac failure in the last month of pregnancy and up to 5 
months after delivery;  
 Absence of an identifiable cause of cardiac failure,  
 Absence of a recognizable structural heart disease prior to the last month of 
pregnancy;  
 And left ventricular dysfunction demonstrated by classic echocardiographic 
criteria, such as depressed fractional shortening <30% or ejection fraction 
<45% and left ventricular end diastolic dimension >2.7 cm/m2.  
The incidence of PPCM is not always known because population-based estimates 
are not available as data is primarily based on case series from single centres. In the 
USA it ranges from 1 per 3000 to 1 per 4000. Some studies conducted in South 
Africa showed an incidence of 100-300 per 100 000 live births. 
Aim of the study:  
The aim of the study was to investigate the factors which contribute to the clinical 
outcomes of peripartum cardiomyopathy (PPCM) at Klerksdorp/Tshepong Hospital 
Complex in Klerksdorp South Africa, by means of quantitative research.  
Methods: 
A single centre, non randomised, retrospective cohort, chart review together with 
prospective assessment of patient outcomes was done on 34 patients attending 
Specialist Medical Outpatient Department Clinic at Klerksdorp/Tshepong Hospital 
Complex from January 2011 to September 2014. The patients would have delivered 
between January 2011 and March 2014. Recruitment followed the inclusion and 
exclusion criteria based on the definition of peripartum cardiomyopathy. The patient 
files were reviewed at the time of diagnosis and at six months looking at the 
background history, therapy, clinical progression and outcome. The last assessment 
was done with the patient. Demographic data, obstetric and medical history, clinical 
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progression measured by serial signs and symptoms were collected. Chest 
radiograph, electrocardiograph and echocardiograms were also registered and 
correlated to the clinical outcome.  
Findings:  
A total of 38 patients were recruited with a diagnosis of peripartum cardiomyopathy. 
Four patients were excluded from the study. Of the 34 patients who completed the 
study 47% recovered, whilst 26.5% remained stable and 26.5% progressively 
declined. Three patients, 8.8% died. Thromboembolic phenomena were noted in 
20.6% of patients whilst 33.3% were on anticoagulants. The period prevalence was 
0.33% (3 per thousand live births). The mean proportion in different clinical outcome 
groups was compared using Tukey’s Studentised Range (HSD) test for result. There 
was a significant difference in the mean proportions between the three groups 
(p=0.0001). In the pairwise comparisons, the mean proportion of the recovered 
group was significantly higher than that of the stable (p<0.05). There was no 
difference in the mean proportion of the recovered and deteriorated groups (p>0.05). 
All the patients received standard cardiac failure treatment. 
Discussion:  
The prevalence of PPCM at Klerksdorp/Tshepong Hospital Complex was higher than 
other parts of South Africa. The clinical outcome distribution from the study faired 
with the reported 50% recovery, 25% stable and 25% progressive deterioration. The 
patients received standard medical therapy. Low usage of anticoagulants could have 
attributed to the high rate of thromboembolic events. Device therapy is indicated in 
refractory heart failure if resources permit. It was recommended that a high-quality, 
large, multicenter prospective study be conducted to better understand the clinical 
outcomes of PPCM and its influencing factors. 
Conclusion: 
PPCM is a rare condition, multifactorial in origin with a good clinical outcome in the 
majority of cases if treated appropriately. It should be considered in any patient who 
presents with acute dyspnea in the perinatal period. Patients with PPCM are being 
optimally treated at Klerksdorp/Tshepong Hospital Complex. Anticoagulation is 
recommended in patients with low ejection fractions. Further, large progressive 
studies are required to fully understand the aetiology and the effect of novel 
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Chapter One: Literature Review 
1.1 Introduction 
As early as the late 18th century, physicians had noted a relationship between 
pregnancy and heart failure.1,2 Fraser (1935) showed that heart failure was one of 
the leading causes of maternal mortality, not due to obstetric complications.3,4 Hull 
and Hidden were the first to document peripartum cardiomyopathy (PPCM) in New 
Orleans in 1936, and then called “toxic” postpartal heart disease.5 Peripartum 
cardiomyopathy is also called postpartum cardiomyopathy (PCMO) and pregnancy-
related heart failure. It is a form of cardiomyopathy which is basically enlargement 
and weakening of the heart associated with ineffective pumping of blood around the 
body.6 
Much research has been done worldwide, with South Africa leading in efforts to 
understand the aetiology, pathophysiology, management and progression of PPCM. 
The leading institutions in this field have been, the Hatter Institute for Cardiovascular 
Research in Africa (HICRA), University of Cape Town and the Soweto 
Cardiovascular Research Unit, University of Witwatersrand (SOCRU).7,8  
One of the clinical trials done in South Africa noted that the use of Bromocriptine in 
the postpartum period was associated with recovery. The study showed that the 
addition of bromocriptine to standard therapy resulted in significant rates of left 
ventricular recovery at 6 months. The study was limited by a small sample size. 
Coupled to this was the aversion of nursing mothers to deprive their babies of milk 
as the drug is used for cessation of lactation.9  
Studies of this nature have motivated and inspired medical scientists to do more 
research in a bid to fully understand the condition so that research knowledge can 







1.2 Statement of the problem 
1.2.1 Background 
Peripartum cardiomyopathy is a form of dilated cardiomyopathy of unknown 
aetiology associated with a high rate of morbidity and mortality, both to the mother 
and the fetus.10 In 2000, the National Heart Lung and Blood Institute (NHLBI), and 
The Office of Rare Diseases workshop recommended that PPCM be defined as: “the 
development of cardiac failure in the last month of pregnancy or 5 months of 
delivery; absence of an identifiable cause of cardiac failure, absence of a 
recognizable structural heart disease prior to the last month of pregnancy; and left 
ventricular dysfunction demonstrated by classic echocardiographic criteria, such as 
depressed fractional shortening <30% or ejection fraction <45% and left ventricular 
end diastolic dimension >2.7 cm/m2”.11 
1.2.2 Nature of the problem 
Peripartum cardiomyopathy is a life threatening condition whose epidemiology, 
aetiology and pathophysiology are poorly understood because of low incidence, 
geographic variation and diversity in manifestation. The prognosis of PPCM remains 
guarded even in the best of care with up to 50% of afflicted women gradually 
deteriorating.12,13 Maternal and neonatal morbidity and mortality reduction are one of 
the most important goals of the Department of Health of South Africa and World 
Health Organisation. In 2000, South Africa joined the rest of the world by signing the 
Millennium Development Goals (MDGs) with targets to reduce child deaths by two 
thirds and maternal deaths by three quarters.14,15 
The relative high incidence of PPCM at Klerksdorp/Tshepong Hospital Complex 
provided a unique opportunity in understanding the pathophysiology and 
prognostication of the condition. This was the rationale of performing the study. 
Knowledge of PPCM epidemiology and clinical outcomes potentially leads to high 
index of suspicion in healthcare professionals, and hopefully, early diagnosis and 





1.2.3 Contributing factors to the problem 
Peripartum cardiomyopathy is a rare condition of unknown aetiology. Making a 
diagnosis of PPCM is daunting to physicians as other identifiable causes of heart 
failure have to be excluded.12 The definition of PPCM requires echocardiograph 
which can be interchangeable with cardiac magnetic resonance (CMR).16,17 In 
primary health care facilities in South Africa and most developing countries, there are 
no ultrasound sound scan machines, let alone echocardiograms. Cardiac magnetic 
resonance is still under development even in the first world. The expertise to 
measure the fraction shortening and ejection fraction is lacking in most physicians. 
There is need for workshops and training programs in this regard. Postpartum 
cardiomyopathy requires a multi-disciplinary effort between obstetricians, 
pediatricians, cardiologists and generalists.18 
1.2.4 Prior research 
The Study Group on Peripartum Cardiomyopathy was founded in 2009 as one of the 
groups in the Heart Failure Association (HFA) committee of the European Society of 
Cardiology (ESC).19,20 It aims to be an international platform for sharing knowledge 
and clinical experience on PPCM. There is growing concern that the previous 
definition is underdiagnosing PPCM as some patients present before the last month 
of pregnancy and after 5 months postpartum threshold.20 
Many such organizations have been formed in an attempt to fully categorise the 
condition. The Hatter Institute of Cardiovascular Research in Africa (HICRA) has a 
Cardiac Disease and Maternity research group that is looking into the pathogenesis 
of PPCM with special attention into the biomarkers.7 One of the landmark studies at 
HICRA was the discovery of the link between bromocriptine and recovery.9,21,22 
1.2.5 What still needs to be done? 
There is so much more that needs to be known about PPCM.10 The aetiology and 
pathogenesis need to be well researched so as to know which patients need to be 
screened antenatal.13 The undertaking of clinical trials in expecting mothers has 
ethical dilemma, as the safety of the mother and unborn child is a priority. It is not 
known how long patients should be on treatment and when to stop. Most case series 
follow up patients for 6 to 12 months. There is need for longer patient follow up.13 
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Patients who develop PPCM are young women who have not completed their 
families and still need to have more children but are advised to use contraception.13 
Research still needs to be done into which parameters to focus on in those who have 
had cardiac recovery and good reserve function with a view to determine which 






















1.3.1 Definition of PPCM  
In 2010 the Study group of Postpartum Cardiomyopathy of the European Society of 
Cardiologist (ESC) defined PPCM as an idiopathic cardiomyopathy presenting with 
heart failure secondary to left ventricular systolic dysfunction towards the end of 
pregnancy or in the months following delivery, where no other cause of heart failure 
is found. It is a diagnosis of exclusion.24 The left ventricle may not be dilated but the 
ejection fraction is nearly always reduced below 45%.20 
1.3.2 Aetiology  
The cause of peripartum cardiomyopathy is unknown.10 There are a number of risk 
factors that have been found to be associated with the disease which include multi-
parity, twin gestation, and breast feeding for an extended period, history of 
preeclampsia, smoking, alcohol, and use of illicit drug, African ancestry and family 
history of the disease.4,11,25 Long term use of tocolytics, age and gestational 
hypertension has also been associated with PPCM. The risk factors are grouped into 
probable and proposed as shown in figure 1.1. Patients with a history of the 
condition are likely to have a relapse or deteriorate in subsequent pregnancies.24 
 






1.3.2.1 Proposed risk factors 
The proposed risk factors for PPCM include being of African ancestry, malnutrition, 
low socioeconomic status, hypertension, smoking and cocaine use.20 A collaborative 
study in Georgia and Tennessee in United States of America showed that African-
American women had a higher risk of developing PPCM.26, 27 
1.3.2.2 Probable risk factors 
Incidence of PPCM has been found to be higher in multiple pregnancy, high parity, 
high gravidity and extremes of reproductive age.1,28,29 The prolonged use of tocolytics 
in preterm labour to suppress uterine contractions has been associated with a 
predilection for developing PPCM.30 
1.3.2.3 Emerging risk factors 
Recent studies have noted an increased risk of PPCM in pre-eclamptics and obese 
patients. Familial genes and previous viral infections including CMV, EBV and HIV 
have been reported to predispose patients to cardiomyopathy.9,13,31  
1.3.2.4 New Developments 
Bromocriptine is a dopamine antagonist which blocks the effects of prolactin, a 
23kDa molecule released from the anterior pituitary. Prolactin degradation product in 
high oxidative states produces a 16kDa subform which is pro-apoptotic and anti-
angiogenetic.21,22 This is associated with reduced cardiomyocyte and endothelium 
metabolism, eventually leading to poor cardiac function.21 
Tumour necrosis factor-alpha (TNF-α) is an inflammatory mediator which is elevated 
in PPCM.32,33,34 Pentoxifylline, a xanthine-derived inhibitor of TNF-α, have been 
found to be associated with favourable outcomes in clinical trials done at Chris Hani 
Baragwanath Hospital, Johannesburg South Africa in 2002. Batchelder et al’s 
systemic review in 2005 suggested the need for large trials to confirm the efficacy 
and safety of pentoxifylline in PPCM.35  
Immunoglobulins (Ig) are anti-inflammatory chemicals produced by the body to 
combat infection. Transfused immunoglobulins in the acute decompensated phase of 
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PPCM failed to show superiority compared to standard therapy in 6 months and 
12months.36    
1.3.3 Epidemiology  
Peripartum cardiomyopathy is a universal condition with incidence rate of 1:3000-
15000.25 The highest rate in the world and Africa are found in Haiti and Nigeria, 
respectively. Peak incidence of PPCM in Nigeria is found in the Hausa tribes of Zaira 
district.10 This has been associated with the postpartum traditional practices of high 
salt intake ‘kanwa’, and lying on heated mud beds for up to two times a day, for 40 
days, in humid conditions in a bid to boost milk production. 10,37  
 
Figure 1.2: The distribution of PPCM in different countries10 
In Asia it is more common in the Chinese, Korean and Japanese women. In the USA 




Figure 1.3: Time of onset of symptoms of peripartum cardiomyopathy in South 
Africa, Germany and USA38 
The incidence of PPCM in Durban and Johannesburg are 1:1000 and 1:3000, 
respectively.18,39 Normally, PPCM presents in the last weeks of pregnancy and first 
months postpartum in previously healthy women. Figure 1.3 presents the time of 
onset of symptoms in relation to delivery in South Africa, Germany and United States 
of America.38 
Peripartum cardiomyopathy affects all age groups of fertile women, though it has 
preponderance for women greater than 35 years.12 In these women there may be 
several confounders as there are likely to be previously undiagnosed diseases. 
Furthermore, diseases like hyperthyroidism, mitral stenosis and hypertension in 
pregnancy can lead to pulmonary edema which can be erroneously diagnosed as 
PPCM.24 Seventy five percent (75%) of PPCM patients are diagnosed within the first 
month after delivery, 45% in the first week postpartum, and 19% diagnosed in the 

























                                                                          
 
 
                                                    
                                                                                                                                                  







Figure 1.4: Proposed factors contributing to the pathogenesis of PPCM. 
(PPCM=peripartum cardiomyopathy)43 
1.3.4.1 Pathophysiology  
It has been postulated that a number of insults to the myocardium prior or during 
pregnancy herald the inflammatory process that is propagated during gestation as 
highlighted in figure 1.3.41 This in concert with the physiological changes that occur 
in pregnancy, further stretches the weakened heart making it fail to adapt thus 
leading to heart failure.11,24 Figure 1.4 illustrates the vicious cycle that leads to the 
propagation of cardiac failure.42 The probable and possible risk factors act as insults 
to the heart.10 This leads to a diseased heart with decreased cardiac output. 
Reduced cardiac function activates the neuroendocrine system with release of 
catecholamines, vasopressin, renin, angiotensin, and aldosterone. These hormones 
result in peripheral vasoconstriction and fluid retention, with inotropic and 
Activation of protective 










dysfunction • Viral antigen persistence 
• Stress activated cytokines 
• Autoimmune responses 
• Genetic factors 
• Micronutrients 
• Microchimerism 
• Increased myocyte apoptosis 
• Excessive prolactin production 
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chronotopic effects on the heart.16,43 There is increase of venous return, cardiac 
afterload and end diastolic volume. Consequently, the energy required to contract by 
the diseased myocardium is escalated.11,20 
 
  
Figure 1.4: Pathophysiology of Peripartum Cardiomyopathy. LV (left ventricle). 
PPCM (peripartum cardiomyopathy).42 
1.3.4.2 Ventricular remodeling 
Ventricular remodeling is a term used to describe the architectural changes that 
occur to the heart after an insult. Grossly, there is pathological increase in left 
ventricular volume and disruption of the normal elliptical chamber configuration to a 
more spherical shape.44 The Valsartan in acute myocardial infarction trial (VALIANT) 
noted three echocardiographic patterns of left ventricular remodeling when the 
ejection fraction was below 35% namely; concentric, concentric hypertrophy and 
eccentric hypertrophy. All these patterns are associated with poor cardiac function.45 
Many case series of PPCM patients who had endomyocardial biopsies showed 
myocarditis. Sanderson et al studied 11 African women and endomyocardial biopsy 























(1) Macroscopically: dilated heart, pale myocardium, endocardial thickening, and 
pericardial fluid.  
(2) At microscopic level: myofibre hypertrophy and degeneration, fibrosis, interstitial 
edema and lymphocytic infiltration were noted on haematoxylin and eosin-stained 
specimen. In addition, an increase in interstitial collagen was found. 24,46 
1.3.5 Presentation 
Table 1.1: Signs and symptoms of PPCM43 
Symptoms Signs 
Shortness of breath at rest or during 
exercise, orthopnoea, paroxysmal nocturnal 
dyspnoea 
Tachycardia, tachypnoea 
Cough Displaced apical impulse 
Fatigue Elevated jugular venous pressure 
Weight gain or weight loss Gallop rhythm 
Somnolence or diminished mental acuity Rales, rhonchi, or wheezes 
Tachypnoea Pedal oedema, hepatomegaly, ascites, 
anasarca 
 
The signs and symptoms of PPCM are summarized in table 1.1. The common 
symptoms include cough, dyspnoea, orthopnoea, paroxysmal nocturnal dyspnoea 
and pedal oedema whilst specific signs are elevated jugular venous pressure and 
gallop rhythm. Pedal oedema and anasarca can be present in other organ 
dysfunction, namely hepatic and renal failure.47 Table 1.2 summarizes the approach 






Table 1.2: Assessments to be made at clinical review47 
Assessment of  
functional capacity 
Chiefly from history, but more objectively by use of New York 
Heart Association class, specific quality-of-life 
Questionnaires, 6-minute walk test, or maximal exercise test. 
Note: not all of these tests are likely to be necessary, or 
appropriate, at each assessment. 
Assessment of fluid  
Status 
Chiefly by physical examination – changes in body weight, 
extent of jugular venous distension, lung crackles and 
hepatomegaly, extent of peripheral oedema, and lying and 
standing blood pressure (postural drop in blood pressure may 
indicate hypovolaemia) 
Assessment of  
cardiac rhythm 
Chiefly by clinical examination, but may require 12-lead 
electrocardiogram (ECG) or 24-hour electrocardiographic 
(‘Holter’) monitoring if there is suspicion of arrhythmia 
Laboratory assessment Checking of serum biochemistry (urea, electrolytes, creatinine) 
is essential, but other tests (such as thyroid function, 
haematology, liver function, level of anticoagulation) may also be 
required depending on the medication prescribed and co-
morbidity 
 
1.3.6 Differential Diagnosis 
Acute shortness of breath, pedal oedema and heart failure can emanate from a host 
of different diseases in the peripartum period. Common ailments are cardiovascular 
and pulmonary in origin. Conditions affecting the heart blood supply, valves or 
musculature can result in poor cardiac output.17 Ischaemic Heart Disease (IHD) 
results in inadequate oxygen supply to the myocardium and reduced ejection 
fraction. Aortic and mitral valve stenosis or regurgitation, eventually leads to heart 
failure.48 The heart can be dilated and loses its effective contractility in 
cardiomyopathy (CMO). Cardiomyopathy can be from alcohol abuse, thyroid disease 
or hypertrophic obstructive cardiomyopathy (HCM), but in most instances the cause 
remains idiopathic. Gestational hypertension or pregnancy induced hypertension and 
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preeclampsia are associated with propagation or precipitation of cardiac failure. 
Pulmonary disease can reduce blood oxygenation, and presents with dyspnoea. 
These conditions include pneumonia, asthma and pulmonary hypertension. 
Infectious causes like tuberculosis are common. Coxsackie, Epstein-Barr virus (EBV) 
are common viral causes of myocarditis. Human immunodeficiency virus (HIV) is 
now the commonest cause of viral cardiomyopathy.16 Metabolic diseases like 
glycogen storage disorders and Duchenne Muscular Dystrophy (DMD) are rare 
causes of heart failure.17,48 
Conditions that can masquerade as heart failure need to be excluded. These are 
obesity, hepatic and renal failure, hypoalbuminaemia, hypothyroidism and severe 
anaemia.16 
1.3.7. Investigations 
Heart failure is the final common pathway from a number of aetiological insults to the 
myocardium.17 A summary to the approach to making a diagnosis of heart failure is 
illustrated in figure 1.5. Many criteria have been used to assist in making a diagnosis 
of heart failure. They include Framingham, Duke and Boston Criterion. These criteria 
combine patient history, examination and investigations in determining the likelihood 
of having cardiac failure.16 Peripartum cardiomyopathy is a diagnosis of exclusion. 
Investigations are done to confirm or refute its presence and determine severity. 
Basic tests like urine analysis and blood work can be the starting point.48 Urine 
analysis (UA) and urine protein: creatinine ratio (UPCR) can be done. Blood tests 
include full blood count (FBC), urea and electrolytes (U&E), liver function tests (LFT), 
thyroid function tests (TFT), erythrocyte sedimentary rate (ESR), C-reactive protein 
(CRP) and cardiac enzymes. Viral, rickettsia, syphilis and Chagas disease 
myocarditis must be excluded by specific antibody tests.24 These tests are used to 
find the aetiology and precipitant of cardiac failure. More so, they are used to stratify 
the severity of disease. Chest X-ray (CXR), electrocardiogram (ECG) and 
echocardiogram are some of the mandatory tests done to visualize the structure of 



















Figure 1.5: Algorithm summarising recommendations for the diagnosis of heart 
failure. (BNP = B-type natriuretic peptide; FBC = full blood count; LFT = liver function 
test; NTproBNP = N-terminal pro B-type natriuretic peptide; TFT = thyroid function 
test; U&E = urea and electrolytes).47 
 
1.3.7.1 B-type natriuretic peptide 
B-type natriuretic peptide (BNP) is a protein produced by the myocytes in response 
to left ventricular strain. BNP has vasodilator, diuretic and natriuretic effects. It 
suppresses the sympathetic drive and the renin-angiotensin-aldosterone system 
(RAAS).16 It is specific to heart failure and is used to confirm the diagnosis in patients 
who present with acute dyspnoea and anasarca.17 Figure 1.5 shows the clinical 
application of BNP in the diagnosis of heart failure. Table 1.3 shows the 
Suspected heart failure 
history, symptoms, and signs 
Seek to exclude heart 
failure through: 
• 12-lead ECG 
• and/or natriuretic peptides 
(BNP or NTproBNP) – where 
available 
Other recommended tests: 
(mostly to exclude other 
conditions) Chest X-ray 
Blood tests: U&Es, creatinine, 
FBC, HIV, TFTs, LFTs, glucose, 
and lipids, Urinalysis, peak flow 
or spirometry 
Both normal  
heart failure unlikely 
consider alternative diagnosis 
One or more abnormal 
Imaging by echocardiography* 
Abnormal 
Assess heart failure severity, 
aetiology, precipitating and 
exacerbating factors and type of 
cardiac dysfunction Correctable 
causes must be identified 
Consider referral 
No abnormality detected 
Heart failure unlikely, but if 
diagnostic doubt persists 
consider diastolic dysfunction 




interpretation of BNP levels. B-type natriuretic peptide is also used to prognosticate 
and monitor treatment in cardiac failure.16 
Table 1.3: BNP interpretation43 
BNP level < 100pg/ml (normal) 100-399pg/ml (raised) >400pg/ml (high) 
Clinical significance Heart failure unlikely  Probable Heart failure 
 
1.3.7.2 Chest radiograph 
The chest radiograph is one of the most accessible and reproducible investigations 
in heart failure. Radiological changes include cardiomegaly and pulmonary 
infiltrates.16 Cardiomegaly is defined as an increase in the cardio-thoracic ratio 
beyond 50%.49 It is a measure of the most lateral borders of the cardiac shadow 
compared to the diameter of the chest at the same level.49,50 Pulmonary infiltrates 
increase with the degree of pulmonary venous hypertension which depicts the mean 
capillary wedge pressure. Below is table 1.4 which illustrates the four stages of 
radiographic findings in congestive cardiac failure (CCF). In chronic stable PPCM the 
chest radiograph may be normal or there will be increased cardiothoracic ratio.49 
1.3.7.3 Electrocardiograph 
The electrocardiogram (ECG) is the recording of electrical activity of the heart.48 In 
heart failure there are no pathognomic changes, but it is performed to exclude other 
causes of heart failure like arrhythmia, myocardial ischaemia, aberrant conduction 
and structural anomalies.24,31 In left ventricular systolic dysfunction non-specific 
changes like dysrhythmia, axis deviation, ST changes and ventricular hypertrophy 







Table 1.4: Radiological changes in Heart Failure49 




I-(Cephalization) 10-20mmHg In upright CXR there is apical blood flow 
II-(Interstitial Oedema) 20-25mmHg Kerley B-lines; thin white lines due to 
interstitial oedema 




>30mmHg Bilateral interstitial infiltrates and bilateral 
pleural effusions 
 
1.3.7.4 Echocardiograph                                                               
Echocardiograph is essentially ultrasound of the heart and is the preferred screening 
and monitoring method to assess cardiac function.51 It assesses the cardiac 
chambers size and presence of intra-cardiac masses, valve morphology, and the 
pericardium for effusion. Below is the Simpson method for calculation of ejection 
fraction which is used to measure cardiac performance.52 
The Simpson Method for Ejection fraction = {(End Diastolic Volume – End 
Systolic Volume)/ End Diastolic Volume} x 100  
Echocardiography is extremely valuable in the diagnosis, monitoring and assessing 
of prognosis in PPCM.53 Ejection fraction and left ventricular end diastolic 
dimensions at the time of diagnosis are predictive of long-term cardiac 
dysfunction.52,54  
1.3.8 Management 
The management of PPCM is similar to other forms of dilated cardiomyopathies.48 It 
aim to improve hemodynamic status, minimize signs and symptoms, and optimize 
the long term outcomes.55,56 The treatment depends on the severity of the disease, 
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and whether it is acute or chronic. Critically ill patients are nursed in the intensive 
care unit with invasive hemodynamic monitoring, ventilator and inotropic support. In 
the acute setting oxygen and intravenous furosemide are administered.16 Figures 1.5 
and 1.6 illustrates the recommended approach to diagnosing and managing PPCM 
by the National Institute of Clinical Excellence (NICE).                                         
In decompensated cardiac dysfunction or acute heart failure syndrome (AHFS), 
diuretics and oxygen are used to alleviate the fluid overload.16 Angiotensin 
converting enzyme (ACEI) inhibitors and beta blockers (BB) are first line therapy in 
heart failure when the patients have stabilized.47 These drugs have been proved to 
have mortality (death) and morbidity (disease) benefit in the Survival and Ventricular 
Enlargement (SAVE) and Cardiac Insufficiency Bisoprolol Study (CIBIS) clinical 
trials, respectively.20,57 If the patient remains symptomatic mineralo-corticosteroid 
receptor antagonist (MRA) are subsequently added as second line therapy.  Digoxin 
is of benefit in sedentary patients with reduced ejection fraction especially if there is 
atrial fibrillation.16 In high-resource centres end stage heart failure (ESHF) patients 
can be considered for cardiac resynchronization therapy (CRT)/ biventricular pacing, 
ventricular assist device (VAD) or heart transplant.11,47 
1.3.8.1 Decompensated Peripartum cardiomyopathy 
Patients with acute decompensated peripartum cardiomyopathy need to be 
managed in intensive care or high dependency units with continuous 
cardiopulmonary monitoring, and maintenance of the airway, breathing and 
circulation systems.17 This is achieved by oxygen supplementation and at times 
intubation with mechanical ventilation. Diuretics are used to alleviate the fluid 
overload whilst monitoring the central venous pressure invasively. If there is 
profound hypotension, inotropic support with dobutamine or dopamine will be 
necessary.40,41 In refractory cardiac failure interventions like intra-aortic balloon 
pump, ventricular-assist device, extracorporeal membrane oxygenation and cardiac 
transplantation are considered if resources permit.16,42 
1.3.8.2 Compensated Peripartum cardiomyopathy 
Management of chronic PPCM patients involves lifestyle changes and 
pharmacotherapy.58 Antepartum, hydralazine and isosorbide dinitrate combination 
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(H-ISDN) is used instead of ACEI as they are teratogenic.40 The table below illustrate 
the different categories of drugs and safety in pregnancy.  
 
Generalist                               














Figure 1.6: Algorithm for the pharmacological treatment of symptomatic heart failure 
due to left ventricular systolic dysfunction. (ACE=Angiotensin converting enzyme 
inhibitors)47 
1.3.8.3 Non-pharmacological management 
Lifestyle changes that aid in the recovery of the ailing heart with an overloaded 
peripheral system include weight reduction, fluid restriction and low salt diet. In acute 
New diagnosis 
Seek specialist advice 





Or if ACE inhibitor 
not tolerated (e.g. due 








If patient remains 
moderately to 
severely symptomatic 
despite optimal drug 
therapy listed above 
Add diuretic 
Diuretic therapy is 
likely to be required 
to control 
congestive 
symptoms and fluid 
retention 
Add digoxin 










or if patient is in 
atrial fibrillation 




heart failure, daily weights and, monitoring of input and output is instituted with the 
aim to achieve a negative fluid balance.16 Salt causes water retention. Low salt foods 
containing less than 150mg per 100g are recommended. Patients are advised to 
drink less than 2 litres of fluids per day.12 Other lifestyles changes that have an 
impact on recovery involve smoke cessation, stress reduction and low fat diet. 
Physiotherapy can assist with graded exercises, and psychologist with psychological 
support.59,60 
Table 1.5: Categories of Drugs in pregnancy61 
Category  
A Adequate and well-controlled studies have failed to demonstrate a risk to the 
foetus in the first trimester of pregnancy, no evidence of risk in later trimesters. 
B Animal reproduction studies have failed to demonstrate a risk to the foetus and 
there are no adequate and well-controlled studies in pregnant women.               
( heparin, methyldopa) 
C Animal reproduction studies have shown an adverse effect on the foetus and 
there are no adequate and well-controlled studies in humans, but potential 
benefits may warrant use of the drug in pregnant women despite potential risks. 
(digoxin, Beta blocker, Furosemide, hydralazine and isosorbide dinitrate 
combination) 
D There is positive evidence of human foetal risk based on adverse reaction data 
from investigational or marketing experience or studies in humans, but potential 
benefits may warrant use of the drug in pregnant women despite potential risks. 
(angiotensin converting enzyme inhibitors, mineralocorticoid receptor 
antagonists, hydrochlorothiazide, warfarin) 
X Studies in animals or humans have demonstrated foetal abnormalities and/or 
there is positive evidence of human foetal risk based on adverse reaction data 
from investigational or marketing experience, and the risks involved in use of 






Many drugs are used in the treatment of PPCM with angiotensin converting enzyme 
inhibitors and beta blockers as first line.61 Table 1.5 illustrates the classes of drugs in 
pregnancy categorized according to safety profiles with examples, whilst Table 1.6 
highlights landmark clinical trials in cardiac failure. 
1.3.8.4.1 Angiotensin converting enzyme inhibitor   
Angiotensin converting enzyme (ACE-I) is located mainly in the lung endothelium cell 
membrane and it converts angiotensin I (decapeptide) to angiotensin II 
(octapeptide).43  Angiotensin II activates the release of aldosterone resulting in water 
and sodium retention, renal efferent arteriolar and systemic vasoconstriction. ACE-I 
attenuates the effects of Angiotensin II, and blocks the degradation of bradykinin, a 
powerful vasodilator. Patients intolerant to ACE-I can be given angiotensin receptor 
blockers (ARB).43 
ACE-I significantly reduce hospitalization and improve morbidity and mortality in all 
functional classes (NHYA I-IV). These drugs are first line therapy in PPCM. Many 
clinical trials have demonstrated ACE-I survival benefit. These drugs slow the rate of 
ventricular remodeling.11,42 
1.3.8.4.1 Beta-blockers  
Beta adrenergic receptor antagonist or beta-blockers (BB) are first line therapy in 
PPCM. These drugs block the cardiac effects of chronic sympathetic stimulation 
which include myocyte toxicity.43 This is not a class effect as only metoprolol, 
bisoprolol and carvedilol are recommended.42 Beta blockers are started at low dose 
and up-titrated to optimal dose over weeks to months. Synergism is demonstrated in 
mortality benefit when BB are used in conjunction with ACE-I. There is a reduction in 







Table 1.6: Major Clinical trials in heart failure. 









CONSENSUS (Cooperative North 
Scandinavian Enalapril Survival) 
 
SAVE (Survival and Ventricular 
Enlargement) 
 
SOLVD (Studies of Left Ventricular 
Dysfunction) 
27% risk  reduction in all cause-
mortality, reduction in 
hospitalization64 
 19% risk reduction in mortality  
with captopril65 
29% risk reduction in  morbidity 






CIBIS/ CIBIS II ( Cardiac  Insufficiency 
Bisoprolol Study) 
MERIT-HF ( Metoprolol CR/XL 
Randomized Intervention Trial in Heart 
Failure) 
COPERNICUS (Carvedilol 
Prospective Randomized Cumulative 
Survival Trial) 
Reduction in all cause-mortality, 
hospitalization and death67,68 
reduction in all cause-mortality 
with metoprolol compared to 
placebo (7.2% vs 11.0%, 
p=0.00009)64 5% decrease in 
deaths in the carvedilol group vs 
placebo.70 
MRI ( e.g. 
spironolactone, 
eplerenone) 
RALES (Randomized Aldactone 
Evaluation Study Mortality Trial) 
EPHESUS (Eplerenone Post-Acute 
Myocardial Infarction Heart Failure 
Efficacy and Survival Study) 
30% risk reduction in deaths and 
progression in heart failure. 35% 
less hospitalization. 15% 
reduction in risk of death.66 
Digoxin DIG (Digitalis Investigation Group) Reduction of hospitalization 




 No survival benefits have been 





1.3.8.4.3 Mineralocorticoid receptor antagonist  
Mineralocorticoid/Aldosterone receptor antagonists (MRA) are potassium sparing 
diuretics. Mineralocorticoid receptor antagonist is an add-on drug to ACE-I and BB in 
heart failure with an ejection fraction (EF) < 35 % and persistent symptoms, NYHA II-
IV.12 Randomised control trials have shown reduction in cardiac failure 
hospitalization and risk of premature death.20 
1.3.8.4.4 Hydralazine and isosorbide dinitrate combination   
Hydralazine and isosorbide dinitrate combination (H-ISDN) is first line therapy in 
pregnancy where teratogenic ACE-I and ARBs are contraindicated. After pregnancy 
it is second line after ACE-I and BB.20 
1.3.8.4.5 Digoxin 
Digoxin is a cardiac glycoside with inotropic effect. It is third line therapy which is 
associated with symptom relief but no survival benefit.16 It is more useful in patients 
with concomitant atrial fibrillation with a fast ventricular response or atrial flatter as it 
delays impulse conduction through the atrioventricular node.43 
1.3.8.4.6 Diuretics 
Low dose loop diuretics can be used in chronic heart failure. Loop diuretics like 
furosemide do not have survival benefit.42 
1.3.8.4.7 Anticoagulation 
Pregnancy is a hypercoagulable state with an increase in prothrombotic factors 
which may persist up to 8 weeks postpartum.20 This is compounded by immobility.10 
In PPCM; the poor cardiac function can result in development of intra-cardiac, 
arterial or venous clots. These can manifest as cerebrovascular accidents, 
pulmonary embolus or deep venous thrombus from thromboembolism.17,48 
Prophylactic anticoagulation is indicated for low ejection fraction (< 35%) and 
therapeutic for thromboembolic phenomena like LV thrombus. Aspirin, heparin and 
warfarin are used for anticoagulation.12 Foetotoxicity of warfarin makes it the 
preferred agent of choice postpartum whilst low-molecular heparin is used in the last 
weeks of pregnancy.20 
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1.3.8.5 Devices  
Patients with intractable PPCM should be considered for cardiac devices. These 
include cardiac resynchronization therapy (CRT) with or without intra-cardiac 
defibrillator (ICD) and ventricular assist device (VAD).16, 20 
1.3.9 Prognosis 
Peripartum cardiomyopathy is a life threatening condition if not diagnosed early and 
managed appropriately.13 The heart failure can be progressive leading to poor effort 
tolerance and poor quality of life, and ultimately death.  Maternal complications 
include; hypoxia, thromboembolism in up to 50%, progressive cardiac failure, 
arrhythmias, and sudden cardiac death.16 Intrapartum misinterpretation of invasive 
haemodynamic monitoring is associated with inadequate treatment because of 
exaggerated concern for the fetus.13 Peripartum cardiomyopathy can be 
misdiagnosed as preeclampsia, which requires a different treatment regime thus 
increasing morbidity and mortality.24  
1.3.10 Complications  
1.3.10.1 Fetal Complications 
Fetal complications may be due to fetal distress either from maternal hypoxia or 
placental hypo-perfusion caused by reduced cardiac output induced by excessive 
diuresis or reduction in blood pressure from aggressive afterload reduction. 
Prematurity, still birth and neonatal death are also among some of the fetal 
complications. 13, 62 
1.3.10.2 Maternal Outcomes 
About 50% of patients with PPCM recover clinically with NYHA I/II and favourable 
echocardiographic finding of good left ventricular function. 23-41% of patients’ left 
ventricular dimensions return to normal. It is associated with a good prognosis.11,51 
Old age and smaller LVESD at diagnosis are predictors of good prognosis.13 
Approximately, 25% progressively decline clinically and eventually succumb whilst 
25% remain stable with poor functional status.12,20 “The usual causes of death in 
patients with PPCM are progressive heart failure, arrhythmia or thromboembolism. 
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The mortality rate related to embolic events has been reported to be as much as 
30%”.56 The majority of the fatalities occur in the first 3 months.23  
1.3.10.3 Predictors of clinical outcome 
In the first 6 months post diagnosis of PPCM there is ventricular remodeling and 
exponential left ventricular recovery.44 The initial LV dimensions and ejection fraction 
did not predict long-term functional outcome in some studies.54 Higher NYHA 
functional class and Fas/Apo-1 at diagnosis are associated with mortality.31 Novel 
findings reported young age and low body mass index at diagnosis as independent 
predictors of mortality.63 
1.3.11 Future Pregnancy 
Long term contraception is advised as future pregnancies are likely to weaken the 
heart especially in those with persistent cardiac failure.24,62,75 “Currently, there is no 
consensus regarding recommendations for future pregnancy after PPCM. 
Nevertheless the risk of developing PPCM, with future pregnancies, remains high. 
Particularly in the presence of If there is persistent left ventricular dysfunction, a 
subsequent pregnancy should be discouraged and avoided.”55,76 
1.3.12 Patient follow-up 
Initially, patients are followed up ideally every fortnight, with the treatment titrated 
against symptoms, blood pressure and heart rate.56 The frequency of visits can be 
reduced in stable patients and vice versa if the condition deteriorates. Exercise and 
work are tailored to the patients’ tolerability.13 Patients are encouraged to exercise 
and to cease when they are not able to complete a sentence because of shortness 
of breath. Sexual activity can be resumed when a patient is able to go up two 
staircases or walk for 275 metres.13,59 The Minnesota Living with Heart Failure 
Questionnaire (MLHFQ) is used to assess the effect of disease and therapy on 
activities of daily living.73 The sum from the 21 questions is the Minnesota score. It 
decreases as the patient improves and conversely with PPCM deterioration. The 
questionnaire is annexed in Appendix F. A 6 minute walk test (6MWT) is used to 
assess physical endurance and monitor recovery objectively.74 The participant walks 
for six minutes on flat ground and effort tolerance is quantified by the degree of 
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shortness of breath, oxygen desaturation, number of stops and blood pressure 
changes.73,74  
1.3.13 Patient compliance and adherence 
Patient education and counselling have been found to be associated with increased 
patient awareness of PPCM and, better self-confidence and self-management which 
translates to better outcomes.59,75 This can be achieved by explaining clearly what 
PPCM is by the doctor and nurse.56,76 In addition, a PPCM condition pamphlet can 
be given to the patient. The health facility should have a supportive system for 
patients with PPCM. Chronic heart failure medication should always be available for 


















Chapter Two: Methods 
2.1  Aim of study  
To investigate the outcomes and the factors which contribute to the clinical outcomes 
of peripartum cardiomyopathy (PPCM) at Klerksdorp/Tshepong Hospital Complex in 
Klerksdorp, South Africa. 
2.2 Research questions 
1. What is the incidence and prevalence of PPCM at Klerksdorp/Tshepong Hospital 
Complex? 
2. What are the clinical outcomes of PPCM? 
3. What are the factors that contribute to the clinical outcomes of PPCM? 
4. How is PPCM managed at Klerksdorp/Tshepong Hospital Complex? 
2.3 Objectives 
 To determine the incidence and prevalence of PPCM. 
 To describe the outcomes of PPCM. 
 To analyze factors that determines the clinical outcomes of peripartum 
cardiomyopathy.  
 To audit the current management of PPCM  
2.4.1 Ethical Consideration 
Research protocol approval was sought from the UKZN Biomedical Research Ethics 
Committee (BREC) before study initiation and this complies with the Declaration of 
Helsinki.77,78,79 The research protocol underwent a formal review process and a 
favourable opinion was given. Concomitantly, permission was granted by the 
Klerksdorp/Tshepong Hospital Complex Patient Support Group (PSG) local review 
board in conjunction with the Northwest province department of Health (NWDH). 
Appendix D and E are the respective ethics approval from BREC and NWDH.  
 
 
2.4.2 Informed consent 
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The study was explained to the patients with benefits, risks, and alternatives 
emphasized.77,78,79 Patients had the right to join or decline participation. No coercion 
was done. The patients retained the right to withdraw from the study at any time. 
Appendix C was condition pamphlet used to help participants to understand PPCM 
and the study. Appendix A is the informed consent form which the participant signed. 
2.5 Research design 
The study included a retrospective review of patient records together with a 
prospective assessment of patient outcomes. The cohort was patients diagnosed 
with PPCM at Klerksdorp/Tshepong Hospital Complex in the Obstetrics department 
and following up in the Medicine department from January 2011 to March 2014. 
Patients who were actively attending the clinic were recruited. A chart review was 
done with the aid of an investigator administered data collection tool (Appendix B). 
Patient information at diagnosis and six months were collated from their medical 
record. The duration between time of diagnosis and last assessment varied from a 
few months to 3 years in participants diagnosed in 2014 and 2011, respectively. The 
last assessment was done on the actual patient on the study visit which coincided 
with the routine review date.    
2.6 Study Area 
The study was performed at Tshepong Hospital, at the Specialist Medical Outpatient 
Department Clinic in Klerksdorp, South Africa. Klerksdorp/Tshepong Hospital 
Complex is made up of two hospitals, Klerksdorp Hospital and Tshepong Hospital. 
These hospitals function as a unit with different specialties in different hospitals. The 
Obstetrics and Gynaecology department is at Klerksdorp Hospital, whilst the 
Medicine department is at Tshepong Hospital.  Pregnant women are followed up at 
Klerksdorp Hospital. If a diagnosis of heart failure is made during the antenatal 
period the gravid woman is referred to the Medical department at Tshepong Hospital 
for further management. After delivery, management is continued at Tshepong 
Hospital.  
The hospital complex is a satellite teaching center for the University of 
Witwatersrand. It is a tertiary level hospital serving districts in the southern west 
parts of Northwest province. These districts include Bloemhof, Christina, Ganyesa, 
Hartbeesfontein, Leeudoringstad, Orkney, Ottosdal, Schweizer-Reneke, Stilfontein, 
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Taung, Wolmaranstad, Vryurg and Taung. In special circumstances it accepts 
patients from the northern parts of Northwest province and the proximal parts of Free 
State province. 
2.7 Study Methods 
2.7.1 Inclusion criteria 
 Women of child bearing age of any ethnicity. 
 Heart failure in the last month of pregnancy or 5 months postpartum. 
 Depressed fractional shortening <30% or ejection fraction <45% and left 
ventricular end diastolic dimension >2.7 on echocardiography. 
 
2.7.2 Exclusion criteria 
 Presence of another identifiable cause of cardiac failure. 
 Presence of a recognizable structural heart disease prior to the last month of 
pregnancy. 
 
2.7.3 Patient recruitment 
Patients who fulfilled the above mentioned PPCM criteria, and had presented with 
new onset symptoms to the departments of Obstetrics and Gynaecology (OBGYN) 
and Internal Medicine in January 2011 to March 2014 were enrolled into the study. 
Recruitment commenced when the UKZN Biomedical Research Ethics Committee 
and Northwest department of health had approved the research protocol. The nature 
of the study was explained to the patient in the language they understood with the 
assistance of the clinic nurse. The informed consent form and condition pamphlet 
were given to the patient for perusal at their own time so that they could fully 
comprehend the study. These documents are attached as appendix A1, A2 and C. 
2.7.4 Study Visit 
Enrolled patients were interviewed using a researcher administered questionnaire on 
the scheduled study visit which coincided with patients’ routine review date. Vital 
signs including blood pressure, pulse, and respiratory rate were collected. This was 
followed by a physical examination. The resident cardiologist who was following up 
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the patients did the echocardiogram. Two-dimensional targeted M-mode 
echocardiograph with Doppler colour flow was used to measure the cardiac 
structural function. The study visit constituted the patient’s last assessment or 
‘current status’.  
2.8 Data Collection 
The data was captured using an investigator administered questionnaire reviewing 
the patient hospital file. The questionnaire is annexed as appendix B. 
2.9 Study limitation 
The study was partly retrospective. The data was sometimes not adequately 
recorded in the charts. During the study visit the outstanding information was 
obtained as much as possible from the patient. There was selection bias as only 
patients who were actively attending the clinic at the time of the study were enrolled. 
The questionnaires were administered by the investigator.     
2. 10 Data analysis 
The data collated was analysed with the aid of a statistician. The demographic data, 
presenting symptoms, examination findings, investigations and clinical outcomes 
were expressed as mode, mean ±SD or median (range). Diagrams, graphs and 
tables were used for data analysis to compare the variables. We tested the 
hypothesis that the mean proportion of participants recovering, stable or 
deteriorating was similar against the alternative that at least one differs using the one 
way Analysis of Variance. Data for each of the categories was presented as 
proportions and the three groups were independent. The Tukey Studentised Range 
(HSD) test was used for pairwise comparisons between the three groups of patients. 
Analysis was performed using SAS 9.3 (SAS Institute, Cary NC) and assumed a 
two-sided analysis. 
2.11 Dissemination of Results 
The results of the research were presented at Klerksdorp/Tshepong Hospital 
Complex in the department of internal medicine weekly meeting. Research 
participants were educated and counselled on clinical outcomes and the findings and 
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recommendations of the project. The information was disseminated with the hope to 
improving clinical practice.  
2.12 Incidence 
The incidence of a disease is defined as the number of new cases of PPCM in a 
given at-risk population over a specified period of time. This is the number of patients 
with newly acquired disease. It is calculated by dividing the number of new cases in 
a given population by total population at risk during that time.80,81   
2.13 Prevalence 
Prevalence is the total number of cases of PPCM at a moment in time. It includes 
new and old cases. 
Prevalence = 
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑎𝑠𝑒𝑠 𝑜𝑓 𝑃𝑃𝐶𝑀 𝑖𝑛 𝑡ℎ𝑒 𝑚𝑒𝑎𝑠𝑢𝑟𝑒𝑑 𝑝𝑒𝑟𝑖𝑜𝑑
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑙𝑖𝑣𝑒 𝑏𝑖𝑟𝑡ℎ𝑠 𝑖𝑛 𝑡ℎ𝑒 𝑠𝑎𝑚𝑒 𝑝𝑒𝑟𝑖𝑜𝑑 
× 100 
In chronic cases the prevalence is greater than the incidence. In epidemics 
prevalence is equal to incidence.80,81 The period prevalence is the summation of 
patients who already had PPCM and the new cases in the period January 2011 to 
March 2014. 
2.14 The clinical outcomes 
The natural progression of PPCM is that 50% of the patients recover, 25% remain 
with heart failure and 25% progressively deteriorate.13 Poor cardiac function is 
associated dizziness, dyspnoea, palpitations, tiredness, and development of clots in 
the heart and vascular system. Patient follow up involved monitoring the above signs 
and symptoms. It also entailed recognition of complications like arrhythmias, 
cerebrovascular accidents, acute pulmonary oedema and venous thromboembolism 
(VTE) in the form of pulmonary embolus and deep vein thrombosis.12 
Recovery was noted by resolution of shortness of breath and fatigue, coupled with 
good effort tolerance.74 Effort tolerance was measured by the New York Heart 
Association (NYHA) functional classification. Class I have no symptoms and 
limitation to ordinary physical activity, whilst Class IV have severe limitation and 
experience symptoms at rest.73 Patient recovery is accompanied with an ejection 
fraction (EF) and fractional shortening (FS) on echocardiography of more than 45% 
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and 30%, respectively. The left ventricular end diastolic volume (LVEDD) will be less 
than 2.7cm2.51 
The study involved the follow up of patients diagnosed with Peripartum 
Cardiomyopathy from January 2011 to March 2014 focusing on clinical outcomes 
and their contributing factors. Clinical progression was assessed at the time of 
diagnosis, at six months and current status. The three clinical outcomes were: 
a) total recovery clinically and on echocardiograph: in this group anti-heart 
failure medication was eventually stopped,  
b) stable, these are patient that remained with heart failure but had mild physical 
limitation: New York Heart Association (NYHA) functional class I/II 
c) progressive deterioration, this group of patients had moderate to severe 
heart failure with profound limitation of activities of daily living: NHYA III/IV.20 
The patient outcome was recorded on the questionnaire in the assessment section. 
 
2.15 Risk factors 
Data on probable, proposed and emerging risk factors for the aetiology of PPCM like 
multiple gestation, multiparity, preeclampsia, socio-economic status, age and 
ethnicity were collated in the demography section of the questionnaire. The clinical 
response was assessed by noting the progression of signs and symptoms. 
Furthermore, special investigations like chest radiograph, electrocardiograph and 
serial echocardiograph were utilised to objectively assess the outcome. 
2.16 Standard of care of PPCM  
Data on how the patients were managed was collated from charts review. At follow-
up review the scripts were reviewed to note whether the drugs were at optimum 
doses. In recovering patients with good heart function a note was made on whether 
dose alteration was made. 
2.17 Patient follow-up after the study  
According to literature, 50% of patients with peripartum cardiomyopathy recover by 6 
months and this coincides with completion of ventricular remodeling.54 This was the 
rationale for ending the inclusion period in March 2014, so that there was more than 
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6 months of follow-up after diagnosis. Patients who had a diagnosis of peripartum 
cardiomyopathy after March 2014 were not included in the study.  
2.18 Research funding 
A scholarship of R30, 000 was obtained from the University of KwaZulu Natal for the 
Master of Medical Science in Internal Medicine (MMedSc (Med)) Degree. The 
scholarship covered tuition remission. The study did not have any external funding 
and there was no conflict of interest. No money was given to patients for 



















Chapter Three: Results                  
3.1 Introduction 
A total of 38 patients with a diagnosis of peripartum cardiomyopathy who attended 
the Specialist Medical Outpatient Clinic between January 2011 and March 2014 
were recruited. Four patients were excluded from the study. Three of them had 
identifiable causes of heart failure. One patient’s file could not be retrieved from the 
records department. The identifiable causes of heart failure were congenital atrial 
septal defect, severe mitral valve stenosis and primary pulmonary hypertension. 
3.2 Demographics 
3.2.1 Age 
The age of the patients ranged from 19 years to 46 years. The mean age was 33.9 
years with standard deviation of 6.1.  
3.2.2 Race 
Ninety-four percent of the research participants were African in origin. No whites, 
Indians or Asians were involved in the study. 
3.2.3 Ethnicity 
The majority of the participants 26 (76.5%) were of the Tswana tribe. The coloured 
(mixed) and Xhosa ethnicities had two recruits each, whilst the Zulu and Sotho had 
one representative each. The regional countries were represented with a patient 
each from Zimbabwe and Mozambique. The indigenous people of Klerksdorp area 
are Tswana speaking. Klerksdorp is a mining and farming community with the 
working class coming from various parts of South Africa.  
3.2.4 Level of education 
Most of the participants were educated and literate. The majority of them attended 
high school as shown in Figure 3.1. Thirty-two percent of the recruits matriculated, 
with 4 (12%) having earned tertiary education. Only 3 (9%) had primary education. 
Of the 34 participants, 5 (15%) were employed and the rest were unemployed. This 
is shown in Figure 3.2. 
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Figure 3.1: Level of Education 

























3.3 Obstetric History 
3.3.1 Date of Delivery   
The study recorded deliveries from 2011 to 2014. The majority of patients delivered 
in 2012 and 2013 with 11 and 15 deliveries, respectively. In 2011 there were 6 
deliveries and 2 in 2014. 
3.3.2 Time of Diagnosis  
The time of diagnosis ranged from -1 to +5 months in relation to the time of delivery 
as shown in figure 3.3. It was obtained by subtracting the date of diagnosis from the 
date of delivery. The highest number of PPCM cases was in the first month 
postpartum. Twelve percent of study patients were diagnosed in the antepartum 
period, with 68% in the first three months postpartum and 20% greater three months. 
Figure 3.3: Time of diagnosis 
3.3.3 Mode of delivery 
Most of the patients had normal spontaneous vaginal delivery, 23 (68%) whilst 11 
(32%) had caesarean section. 
3.3.4 Number of pregnancy 
The gravidity (number of pregnancies) and parity (number of deliveries after 24 













Figure 3.4: Parity and gravidity 
3.3.5 Hypertensive disorders in Pregnancy 
Gestational hypertension (HTN) was noted in 20 (58.8%) whilst 17 (50%) went on to 
develop pregnancy induced toxaemia (PET). 
3.3.6 General obstetric history 
There were 5 (15%) neonatal deaths in the study participant. In the postpartum 
period, 18 (53%) breastfed their children and 28 (82%) used contraception as a 
method of prevention for further pregnancies. Only 3 (9%) of the patients who did not 
breastfeed received bromocriptine. History of PPCM in prior pregnancy, and multiple 
gestation were noted in 2 (6%) of patients.  
3.4 Medical History 
3.4.1 Hospital admission 
The average number of hospital admissions in acute decompensated heart failure 
was 1.7. Eighteen percent of the participants were admitted in Intensive Care Unit as 






















Figure 3.5: Intensive Care Unit admission 
Figure 3.6: Number of days in ICU 
3.4.2 HIV status 
Fifty-three percent of the participants were HIV negative, whilst 47% were HIV 
positive. Previous history of tuberculosis (TB) was found in 14.7 % (5).  
3.5 Incidence and Prevalence 
3.5.1 Incidence 
The incidence rate of PPCM in the period January 2011 to March 2014 was 34. All 
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The prevalence of PPCM at Klerksdorp/Tshepong in the period January 2011 to 
March 2014 was 51. This included new cases (incidence) and old patients who had 
PPCM and were being followed up at Specialist Medical Outpatient Department. The 
number of live births in Obstetrics department of Klerksdorp/Tshepong Hospital in 
the 39 months was 15561. 
Prevalence = 
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑎𝑠𝑒𝑠 𝑜𝑓 𝑃𝑃𝐶𝑀 𝑖𝑛 𝑡ℎ𝑒 𝑚𝑒𝑎𝑠𝑢𝑟𝑒𝑑 𝑝𝑒𝑟𝑖𝑜𝑑( 51)
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑙𝑖𝑣𝑒 𝑏𝑖𝑟𝑡ℎ𝑠 𝑖𝑛 𝑡ℎ𝑒 𝑠𝑎𝑚𝑒 𝑝𝑒𝑟𝑖𝑜𝑑 (  15561 )
× 100 
                  =0.3277% 
This translates to 3 per 1000 live births.76  
3.6 Patient Presentation 
The symptoms and signs at diagnosis, six months and current state of the 
participants were used to assess clinical progression. 
3.6.1 Symptoms 
Patient symptoms were followed up sequentially from time of diagnosis, 6 months 
and last assessment. Overall, there was a reduction in the intensity of symptoms. 
The trend for dyspnoea, cough and leg swelling are shown in figure 3.7.   














3.6.2 Physical Findings 
Physical signs were assessed at the same interval times as the symptoms. Mostly, 
there was an improvement in all physical signs as shown in figure 3.8. 
Figure 3.9: Physical findings 
3.6.3 New York Heart Association (NYHA) functional status 
Most patients showed improvement in physical activity to full recovery. At diagnosis 
there were 41.20% of participants in class IV and 14.70% in class I. Beyond six 
months 2.90% were in class IV and 58.80% were in class I. Detailed variations in the 

















Figure 3.9: New York Heart Association functional status 
3.7 Investigations 
3.7.1 Chest radiograph 
The chest radiograph findings at diagnosis are shown in Table 3.1.  













patients 76.47% 91.18% 61.76% 85.29% 44.12% 41.18% 
 
3.7.2 Electrocardiography 
Electrocardiograms (ECG) of study patients at diagnosis were reviewed and 
tachycardia was noted in 76.5% (26) of participants, and 67.6% (23) had ventricular 
hypertrophy. Aberrant ventricular conduction (bundle branch block) was found in 


































The mean LVEDD at diagnosis is 57.0 with a standard deviation of 7.9 which greater 
than the up limit of normal of 55 millimeters (mm). At last assessment it had 
normalized to 53.6mm. The mean ejection fraction at diagnosis was 33.5, and 
increased to 43.7 at last assessment. The fractional shortening mean was 16.02% at 
diagnosis and increased to 23.38%, at last assessment.  Tables 3.2, 3.3 and 3.4 
show the mean LVEDD, EF and FS over the three periods. 
Table 3.2: Left Ventricular End Diastolic Dimension (LVEDD) 

















Table 3.3: Ejection Fraction (EF) 
Normal range (55-
70)% 










Table 3.4: Fractional Shortening (FS) 
Normal range (25-
45)% 














All participants were treated with first line therapy which consist of an angiotensin 
converting enzyme- inhibitor (ACE-I) and beta-blocker (BB). The ACE-I received was 
either perindopril or enalapril, whilst the BB was carvedilol. Spironolactone a 
mineralocorticoid receptor inhibitor (MRI) was prescribed to 94.12% of participants. 
All patients were treated with furosemide in the acute decompensated stage of heart 
failure. Digoxin was used in 33.33% of patients. Anticoagulants were also prescribed 
in 33.33% of patients. Aspirin, clexane and warfarin were used for anticoagulation. 
Table 3.5 shows the different types of medications taken by the recruits and their 
frequency. 
Table 3.5: Pharmacotherapy 
Drug type ACE-I BB MRI Digoxin Anticoagulation Loop 
Diuretics 
% use of 
participant  
100% 100% 94.12% 33.33% 33.33% 100% 
 
3.9 Thromboembolism 
The table below shows the complication rates from thromboembolic events 
Table 3.6: Thromboembolism 
 Stroke Pulmonary Embolus Deep Venous Thrombus 
% of participants 
affected 
5.89% 2.94% 11.76% 
 
3.10 Patient Outcome 
Patient outcome was stratified into three categories: recovered, stable and 
deteriorated. Figure 3.10 shows the distribution of patient outcome. 47% of patients 
recovered, whilst 26.5% remained stable and 26.5% deteriorated. The mortality rate 
was 9%. The year of diagnosis was correlated with clinical outcomes in figure 3.11. 
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In year 2012 and 2013 there were the highest proportion of patients who recovered 
whilst 2011 and 2014 was otherwise. 
Figure 3.10: Patient outcome 
Figure 3.11: Year of diagnosis with patient outcome 
The mean left ventricular ejection fraction (LVEF) of study patients generally 
increased in the groups that recovered and remained stable whilst there was a 






























Figure 3.12: Mean LVEF at diagnosis, 6 months and last assessment  
Figure 3.13 compares the clinical outcomes of the patients who breastfed and those 
that did not. Most of the study patients recovered. The patients who did not breastfed 
had more participants who deteriorated.  
Figure 3.13: Breastfeeding and clinical outcome 
at diagnosis 6 months last assessment
recovered 36.36% 44.25% 57.20%
stable 29.32% 35.39% 36.97%































Figure 3.14: Relationship between clinical outcomes and risk factors 
Figure 3.15: Relationship between clinical outcomes and interventions 
The relationship between clinical outcomes with risk factors and interventions are 
shown in fig 3.14 and 3.15, subsequently. Retroviral positive patients had the highest 
fraction of patients who recovered, whilst those with prior history of tuberculosis and 
neonatal death deteriorated. The outcomes of HIV positive and negative patients 
were equivalent with 56% and 50% recovering, accordingly. Of the patients who 
deteriorated, 22% were seronegative whilst 25% were seropositive. The average 
























CD4 count of study participants was greater than 400 and 82% were not on 
antiretroviral. Two patients had CD4 counts of less than 200 and both of them 
recovered.  
Risk factors like gestational hypertension and preeclampsia had comparable clinical 
outcomes, so was patients with thromboembolic phenomena.  Vaginal delivery was 
the intervention noted to have the highest proportion of patients recovering. Patients 
were noted to deteriorate than recover if there had been a history of ICU admission 
and inotropic support.  
 
Figure 3.16: Distribution of the mean proportion in different groups 
Appendix H shows the relationship between the risk factors and clinical outcomes. 
The distribution of the mean proportion in different clinical outcome groups is shown 
in figure 3.16. There was a significant difference in the mean proportions between 
the three groups (p=0.0001). In the pairwise comparisons, the mean proportion of 
the recovered group was significantly higher than that of the stable (p<0.05). There 
was no difference in the mean proportion of the recovered and deteriorated groups 
(p>0.05). Appendix I show the comparison of means of proportions in the different 
groups calculated using Tukey’s studentised range (HSD) test for result. 
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Chapter Four: Discussion and conclusions  
The aim of the study was to investigate the outcomes and factors which contribute to 
the clinical outcomes of peripartum cardiomyopathy (PPCM) at Klerksdorp/Tshepong 
Hospital Complex in Klerksdorp, South Africa. There were four overall objectives, 
including determining the incidence and prevalence of PPCM, describing the 
outcomes and analyzing the factors that determine the clinical outcomes and 
auditing the management of PPCM. 
4.1: Demographics 
Most of the study participants were black Africans who constitute 74% of the 
population in Klerksdorp. Most Africans seek medical attention in public hospitals 
compared to other races, hence the absence of Whites, Indians and Asians. Study 
participants were of low socio-economic status, with 85% unemployed and only 12% 
having obtained tertiary level education. The poor utilize health services in the public 
sector whilst the middle and upper classes are likely to be on medical aid and use 
private hospitals. This concurred with earlier studies in Haiti, Nigeria and USA where 
under privileged women were likely to develop PPCM.7,8,10,31   
Peripartum cardiomyopathy has been found to be higher in extremes of reproductive 
age.12 It has a predilection to older woman, of age greater than 30.17 The study 
average age of 33.9 was central. Risk factors like hypertensive disorders during 
pregnancy and multiparity were noted in more than 50% and 91% of participants, 
correspondingly.12,16 In contrast, Elkayam et al, found approximately a third (27-30%) 
of presentations to be primiparous women.82 Few patients in the primary data had 
prior history of PPCM and multiple gestation.61 Due to the design of the study some 
obstetric data like antepartum and intrapartum management could not be obtained, 
henceforth some risk factors like prolonged use of tocolysis could not assessed.  
4.2: Incidence and Prevalence of PPCM 
The prevalence of 0.33% is higher than rates in previous studies done in Durban and 
Johannesburg of 0.15% and 0.3%, respectively.18,39 The study prevalence was 
equivalent to the world’s highest rates of 0.35%, recorded in Haiti, Niger and 
Nigeria.10 The variation in incidence rates could be a result of geographic and 
reporting difference.20 According to Sliwa et al, the unavailability of echocardiography 
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in some areas may lead to over reporting of PPCM.57 Internationally, there has been 
an increase in the incidence of PPCM attributable to enhanced awareness through 
research and publication.38,57,83 In addition, national and international PPCM 
registries like EURObservational Research Programme (EORP) of the European 
Society of Cardiology is aiding in disease profiling across the world with 90 
participating centres in 42 countries 20,84 
In a study done by Desai and Moodley in South Africa, no patients were diagnosed 
with PPCM before delivery.39 On the contrary, 12% of our study participants were 
diagnosed prior to delivery with German and USA having 17% and 24%, 
respectively.38 In general, most patients are diagnosed in the first three months post-
delivery.10 PPCM is a diagnosis of exclusion hence requires the healthcare 
professional to have a high index of suspicion.10 The astute medical practitioner has 
to be equipped with good clinical acumen to distinguish the signs and symptoms of 
cardiac failure, and echocardiography skill to comprehensively make a diagnosis of 
PPCM.18 The availability of both these factors in industrialised countries and at 
Klerksdorp/Tshepong Hospital Complex could have attributed to the diagnosis being 
made early. 
4.3: Clinical outcomes 
The clinical outcomes were stratified into three groups, namely, recovered, stable 
and deteriorated. The research outcomes were similar to that of recent studies 
performed in other countries. Generally, 50% of patients recover, 25% remain stable 
and 25% progressively deteriorate.16 Study outcomes concurred, as 47% recovered, 
26.5% remained in a stable state whilst 26.5% gradually deteriorated. Overall, the 
signs and symptoms of cardiac failure improved from the time of diagnosis to the last 
assessment. Notably, the proportion of patients with NYHA functional status class I 
improved from 14.7% at diagnosis to 58.8% in their last assessment. The study 
maternal mortality rate of 9% was low. Reported mortality rates range from 2-50% 
with half of them occurring within 3 months of delivery.10,30 Neonatal mortality rate 
was 4%. The high percent of patient recovery and low maternal and neonatal 
mortality rates at Klerksdorp/Tshepong Hospital Complex may be accredited to the 
high quality of care with a multi-disciplinary approach involving the obstetricians, 
paediatricians and physicians.  
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The CXR findings at diagnosis were consistent with acute decompensated cardiac 
failure. Chest radiograph is recommended in the antepartum period as there is 
negligible radiation exposure to the foetus. Other centres are withholding the infant 
shielding practice.13 Electrocardiogram results at diagnosis were non-specific with 
sinus tachycardia and ventricular hypertrophy.  
The echocardiographic definition of PPCM is fractional shortening <30% or ejection 
fraction <45% and left ventricular end diastolic dimension >2.7 cm/m2. The mean 
fractional shortening (FS) and left ventricular end diastolic dimension (LVEDD) were 
initially deranged at diagnosis and eventually normalised at last assessment. The 
mean ejection fraction remained lower than normal throughout the study. Ordinarily, 
the echocardiographic parameters of patients with PPCM improve.17 Despite, patient 
recuperation with restoration of normal ejection fraction and functional status, 
residual cardiac myocyte damage  remains at microscopic level.17 This underscores 
the need for dobutamine stress test which is the gold standard for detecting vestigial 
cardiac dysfunction. Objective recommendations for future pregnancy can be made if 
there is full recovery of LV function on both echocardiography and dobutamine stress 
echocardiography as adverse outcomes are relatively low.13,62 Patients with 
persistent cardiac failure should be advised against pregnancy because the heart 
cannot adapt to the increased workload.57 Johnson-Coyle et al, reported a 19% 
higher risk of maternal death in women with previous PPCM.55 Six percent of our 
study patients had prior PPCM in their first pregnancy succeeded by normalisation of 
ejection fraction before their subsequent pregnancy. All of them had a relapse of 
PPCM followed fully recovery in the second pregnancy.   
4.4: Analysis of factors that determine clinical outcomes 
The past medical history, clinical presentation, investigations and management of 
study participants were correlated with the clinical outcomes. Appendix H shows the 
relationship between risk factors and clinical outcomes. The mean proportion in 
different clinical outcome groups was compared using Tukey’s Studentised Range 
(HSD) test for result. There was a significant difference in the mean proportions 
between the three groups. In the pairwise comparisons, the mean proportion of the 
recovered group was significantly higher than that of the stable but there was no 
difference in the mean proportion of the recovered and deteriorated groups. 
The mean left ventricular ejection fraction (LVEF) of study patients progressively 
increased in the recovered and stable groups whilst there was a gradual decline in 
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the group that deteriorated. Fett et al, followed up patients with PPCM for over five 
years at Albert Schweitzer District hospital in Haiti and noted a gradual increase 
cardiac function on echocardiography well beyond the initial 6-12 months after 
diagnosis.41,85 The study time of diagnosis ranged from 2011 to 2014. It was noted 
that patients who recovered and remained stable followed a normal distribution. 
Patients who deteriorated had peaks in 2011 and 2014. This could be explained by 
the study design being retrospective and quasi-prospective. Most of the patients who 
were diagnosed in 2011 and 2012, and had recovered, no longer actively attending 
Klerksdorp/Tshepong Hospital Complex were not recruited into the study.  
Bromocriptine, a dopamine analogue that inhibit the secretion of prolactin has been 
associated with prevention of cardiac dysfunction and progressive dilation that 
occurs in PPCM when added to standard therapy.38,83 The use of bromocriptine and 
not breastfeeding has been topical lately, with many physicians divided on whether 
to use it or not. Currently, there is not enough evidence to support the use of 
bromocriptine as standard PPCM therapy as large, multicenter, randomized, 
controlled studies are in progress.55,60,83 Hilfiker-Kleiner et al, discovered that patients 
with PPCM had low levels STAT3 protein, and raised levels of activated cathepsin D 
and 16-kD prolactin.9,21,22,,20,38,83 Lactation is associated with elevated prolactin 
serum levels. The study clinical outcomes of breastfeeding mothers and those who 
did not were almost equivalent. 
Sub-Saharan Africa has been greatly affected by the HIV/AIDS pandemic.86,87 In the 
study almost half of the participants were seropositive. There was no significant 
difference between the clinical outcomes of those who were HIV positive and 
negative. A diagnosis of HIV cardiomyopathy was unlikely because the patients met 
the criteria for PPCM. However, the role of HIV as an insult leading to myocarditis in 
the pathogenesis of PPCM cannot be refuted.86,87,88,89 This principle could apply also 
to the patients with prior history of tuberculosis. There was no literature on TB 
myocarditis and PPCM. In a study by Forster et al, HIV infection did not influence 
clinical outcome.86,87 Non-dilated ventricles often found at presentation on 
echocardiograph in HIV cardiomyopathy can be used as the distinguishing feature 
from PPCM.20 Due to the fact that the study sample size was small, the association 





4.5 Audit of the management of PPCM 
All patients received standard therapy. The acute and chronic management of heart 
failure was in line with the ESC, NICE and Heart Failure Society of South Africa 
(HeFSSS) guidelines.20,47,57 Medications were adjusted in accordance with patients’ 
NYHA functional class, vitals and echocardiographic findings.  
Notably, only 33.33% of the patients received anticoagulation and 20.59% had 
thromboembolic events, namely, cardiovascular accidents, pulmonary embolus and 
deep venous thrombus. Anticoagulation is indicated in patients with PPCM with 
ejection fraction of less the 35% or if there is a left ventricular thrombus.13,18,55,90 The 
low usage of anticoagulation could have attributed to the high thromboembolic 
events in the study.  
Refractory heart failure is not being managed adequately because of the lack of 
expertise and resources. These patients require device therapy or cardiac 
transplantation.16,55 
4.6 Limitations of the study. 
The study was a single-centre, non-randomised and partly retrospective at 
Klerksdorp/Tshepong Hospital Complex. The complex is a public hospital hence 
affluent patients were not involved in the study. The patient antenatal care (ANC) 
files with perinatal history were not reviewed due to technical issues. At the hospital 
there was no formal medical conditions database, henceforth it is highly probable 
that a sampling error could have been introduced by not capturing all patients with 
PPCM. More so, patients who had been down referred or recovered, and no longer 
actively attending the clinic were not enrolled. Despite the fact that, the study 









Peripartum cardiomyopathy is a rare condition which needs consideration in any 
patient who presents in the perinatal period with dyspnoea.90 Physicians and patients 
alike need education on current issues regarding aetiology, pathophysiology, 
management and prognosis of PPCM. It is an unfamiliar condition with a high 
prevalence in developing countries. It is one of the reversible causes of heart failure, 
and is associated with a high morbidity and mortality if not diagnosed early. The 
study endeavored to investigate the clinical outcomes of postpartum cardiomyopathy 
at Klerksdorp/Tshepong Hospital Complex in terms of prevalence, management, 
clinical outcomes, and factors affecting the outcomes. By and large, the study 
objectives were achieved. 
The study prevalence of 3 per 1000 live births was higher than previous studies in 
South Africa. It was equivalent to countries with the highest rates in the world. The 
level of patient care at Klerksdorp/Tshepong Hospital Complex was comparable to 
industrialised countries, with 12% of patients being diagnosed in the antenatal period 
and 47% recuperating. Patients who remained stable and those who deteriorated 
were 26.5% apiece. In general, patients’ symptoms and echocardiograph 
parameters improved from the time of diagnosis to the last assessment. The mean 
proportions between the patients, who recovered, remained stable and those who 
deteriorated were significantly different. 
Basing on results from the study, the following recommendations were made. 
Peripartum cardiomyopathy is an intricate condition which requires a multidisciplinary 
approach involving anaesthesiologists, cardiologist, obstetricians, physicians and 
paediatricians in order to deliver optimal care for the mother and fetus. In view of the 
limited data available, there is need to perform larger, multicentre, prospective 
studies with longer follow up periods to adequately describe the disease and, test the 
safety and efficacy of novel therapies like bromocriptine. Patients with intramural 
thrombus or low ejection fraction less than 35% should be anticoagulated. The 
relationship between PPCM and the dual epidemic of HIV/AIDS and TB need to be 
elucidated. The creation of a patient condition database at Klerksdorp/Tshepong 
Hospital Complex is also proposed. Finally, it is advised that hospitals be 
encouraged to participate in local and international PPCM registries.  
53 
 
The study was the first of such a kind at Klerksdorp/Tshepong Hospital Complex and 
it set the stage for future studies. The results were presented to the local health care 
practitioners and policy makers with the hope of translating research knowledge into 
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Appendix A1: Information sheet and Consent Form in English 
Dear patient,  
You are kindly invited to participate in this study, which is explained in the 
information you have received. I am a master’s student at the University of KwaZulu 
Natal, School of Medicine in the College of Health Sciences. I will be conducting the 
study; it is part of the requirements for my Masters of Medical Science degree in 
Medicine (MMedSc (Med)).  
The study will take place at Tshepong Hospital in Klerksdorp at the medical 
outpatient department. You will be asked questions on how you are feeling. Your 
hospital file will be reviewed with special attention to your previous investigations. 
Your progression since diagnosis will be noted. An electrocardiogram (heart tracing), 
and ultrasound scan of the heart (echocardiogram) will be done. Your medication will 
be reviewed and adjusted. Your name and personal information will remain 
confidential. If you agree to participate you will retain the right to withdraw at any 
time without change or compromise to the care you receive in the clinic. 
This study has been ethically reviewed and approved by the UKZN Biomedical 
research Ethics Committee (BREC). The approval number is BE376/14. You can 
contact BREC at:  BIOMEDICAL RESEARCH ETHICS ADMINISTRATION                                               
Research Office, Westville Campus, Govan Mbeki Building                                                                                                                                                                                                                       
Private Bag X 54001, Durban 4000, KwaZulu-Natal,  SOUTH AFRICA                                                                                                                                                                                                                                                                                                                                                                                                                                      
Tel: 27 31 2604769 - Fax: 27 31 2604609                                                                                        
Email: BREC@ukzn.ac.za 
I (Name of Patient)__have been informed about the study entitled Investigations into 
the clinical outcomes of postpartum cardiomyopathy at Klerksdorp/Tshepong 
hospital complex by Dr Farai Russell Sigauke. I understand the purpose of the study. 
I have been given an opportunity to answer questions about the study and have 
been given satisfactory answers to my questions. I declare that my participation in 
this study is entirely voluntary and that I may withdraw at any time without affecting 
any treatment or care that I would usually be entitled to. 
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Signature of patient………………………………     date ………. 
Signature of witness …………………………….      date……….. 























Appendix A2: Information sheet and Consent Form in Tswana 
Molwetsi yo o rategang,  
O kopiwa go nna le seabe mo patlisisong eno, e e tlhalosiwang mo tshedimosetsong 
e o e amogetseng. Patlisiso eno e tlile go tsamaisiwa ke nna mme e okametswe ke 
University of KwaZulu Natal, School of Medicine in the College of Health Sciences. 
Ke bontlhanngwe jwa dilo tse di batlegang mo dikiriing ya me ya Masters of Medical 
Science in Medicine (MMedSc (Med)).       
 Patlisiso eno e tlile go diragalela kwa Tshepong Hospital kwa Klerksdorp kwa 
lefapheng la tsa kalafi la balwetse ba ba okelwang kwa ntle ga bookelo. O tlile go 
bodiwa dipotso tse di malebang le kafa o ikutlwang ka teng. Faele ya gago ya mo 
bookelong e tlile go sekasekiwa go etswe tlhoko ditlhatlhobo tse di dirilweng mo go 
wena mo nakong e e fetileng, go bona kafa o tswelelang ka teng. Leina la gago le 
tshedimosetso ya gago ya poraefete e tlile go nna e le khupamarama. Fa o dumela 
go nna le seabe, o tlile go tswelela o na le tshwanelo ya go ikgogela morago ka nako 
epe fela kwantle ga gore tlhokomelo e o e bonang mo tliliniking e fetoge kgotsa gore 
o ineele mo go seno.                                                                           
Patlisiso eno e sekasekilwe le go rebolwa go ya ka tsa maitsholo a mantle ke UKZN 
Biomedical Research Ethics Committee (BREC). Nommoro ya thebolo ke BE376/14. 
O ka nna wa ikgolaganya le BREC mo nommorong eno: BIOMEDICAL RESEARCH 
ETHICS ADMINISTRATION, Research Office,Westville Campus, Govan Mbeki 
Building, Private  Bag X 54001, Durban 4000, KwaZulu-Natal,  SOUTH AFRICA  
Tel:27312604769                                                                                                                                                                                                          
Fax:27312604609, Email:BREC@ukzn.ac.za                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
Nna (Leina la Molwetse)__ke sedimoseditswe ka patlisiso e e bidiwang 
Investigations into the clinical outcomes of postpartum cardiomyopathy at 
Klerksdorp/Tshepong hospital complex e e dirwang ke Dr Farai Russell Sigauke. Ke 
tlhaloganya gore boikaelelo jwa patlisiso eno ke eng. Ke filwe sebaka sa go botsa 
dipotso tse di leng kaga patlisiso eno mme ke filwe dikarabo tse di nkgotsofatsang. 
Ke itsise semmuso fano gore ke nna le seabe mo patlisisong eno ka go ithaopela 
seno le gore nka nna ka ikgogela morago ka nako epe fela kwantle ga gore seo se 
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ame kalafi ya me kgotsa tlhokomelo ya me e ka gale ke neng nka tshwanela go e 
amogela.     
                                                                                               
Tshaeno ya Molwetse……………………………… Letlhatshi ……….                                      
Tshaeno ya  Basupi …………………………….      Letlhatshi……….                                          




















Appendix B: Data Collection Sheet 
 
Study code: ………………………………….                 Age:………… 
Race:………………………….                                      Ethnicity:………………… 
Suburb:…………………………….                               Level of education:………. 
Occupation: ………………………. 
Date of Delivery:    /   /                                                  Child Alive: N/Y 
Date of Dx:      /   /                                                          
Background hx 
OBGYN hx:  
Gestation
al HTN 








N/Y N/Y NVD/CS   N/Y N/Y N/Y N/Y N/Y 
 
ICU Admission: N/Y                                        Number of Days in ICU:  
Inotropic Support: N/Y                                     Ventilator support: N/Y  
Number of admissions for cardiac failure since diagnosis: 
HIV status (  / /  ) CD4(  /  /  ) VL (  /  /  ) 









TDF FTC 3TC EFV AZT D4T ABC Aluvia 
N/Y N/Y N/Y N/Y N/Y N/Y N/Y N/Y 
 
Previous/ Current Tuberculosis:  N/Y                   Anti-Tuberculosis Treatment: N/Y 
Current Anti- heart failure treatment: 
 ACE BB MRI Digoxin Anticoagulation Diuretic 
 N/Y N/Y N/Y N/Y N/Y N/Y 
Date started       
Type       







Venous Thromboembolism (VTE) 
Stroke: N/Y                                                         Pulmonary Embolus (PE): N/Y 







 At diagnosis After 6 months Current 
Dyspnoea N/Y N/Y N/Y 
NYHA class 1/2/3/4 1/2/3/4 1/2/3/4 
Orthopnoea N/Y N/Y N/Y 
pillows used 1/2/3 1/2/3 1/2/3 
PND N/Y N/Y N/Y 
Leg swelling N/Y N/Y N/Y 
Cough N/Y N/Y N/Y 
Weight gain N/Y N/Y N/Y 
Chest pain N/Y N/Y N/Y 
Tachypnoea N/Y N/Y N/Y 
Fatigue N/Y N/Y N/Y 
Dizziness N/Y N/Y N/Y 
Palpitations N/Y N/Y N/Y 
Syncope N/Y N/Y N/Y 
Headache N/Y N/Y N/Y 
Somnolence N/Y N/Y N/Y 








 At diagnosis At 6 months Current 
General JACCOL JACCOL JACCOL 
BP normal N/Y N/Y N/Y 
RR normal N/Y N/Y N/Y 
Pulse normal N/Y N/Y N/Y 
Temp. normal N/Y N/Y N/Y 
Weight gain N/Y N/Y N/Y 
Cardiovascular 
Increased JVP 
N/Y N/Y N/Y 









Gallop N/Y N/Y N/Y 
Pulse character  N/Y N/Y N/Y 
Pulse volume  N/Y N/Y N/Y 
Cold & clammy N/Y N/Y N/Y 
Pedal oedema N/Y N/Y N/Y 
Respiratory 
Tachypnoea 
N/Y N/Y N/Y 
Basal crackles N/Y N/Y N/Y 
Cyanosis N/Y N/Y N/Y 
Wheezes N/Y N/Y N/Y 
  Breath sounds N/Y N/Y N/Y 
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Abdomen At diagnosis At 6 months Current 
Hepatomegaly N/Y N/Y N/Y 









focal deficits N/Y N/Y N/Y 
                                                                                                                                                  
ECG at diagnosis:  
Rate: B/N/T Sinus Rhythm : N/Y Axis: N/Y BBB: N/Y LVH:N/Y RVH:N/Y 
 
ECHO:  
Dimensions  At Diagnosis At 6 months Current Normal values 
LVEDD    (36-55mm)  
LVESD    (20-40mm) 
EF    (55-70%) 
IVSsd    (6-11mm) 
IVSdd    (7-11mm) 
FS    (25-45%) 
AR    Mild/Mod/Severe 
TR    Mild/Mod/Severe 
MR    Mild/Mod/Severe 
RWMA     




CXR at diagnosis: 





































Appendix C: PPCM Patient Pamphlet 
What is Peripartum Cardiomyopathy (PPCM)? 
English: It is heart failure which occurs in the last month of pregnancy or 5 months 
after in someone without any other reason, serve for the pregnancy itself.   
Tswana: Ke bolwetsi jwa pelo bo bo tlhagelelang mo kgweding ya bofelo ya 
boimana kgotsa kgwedi tse tlhano morago ga go belega. Bo diriwa ke mabaka a a 
sa itsegeng. 
 
Who gets it?  
English: Any pregnant woman can develop PPCM 
Tswana: Mosadi mongwe le mongwe yo o mo mmeleng/ o ithweleng. 
 
What will you be feeling? 
English: It presents with shortness of breath, chest pain, fatigue and leg swelling 
Tswana: Bo bonagala ka go hupelwa, setlhabi mo pelong, letsapa le go ruruga 
maoto.  
 
How do doctors make the diagnosis?  
English: A couple of tests are done to ascertain the diagnosis and stratify the 
severity of the disease. These include chest x-ray, ECG, blood tests, and 
echocardiography/ECHO (ultrasound scan of the heart) 
Tswana: go dirwa diteko tse di latelang go batlisisa ka ga bolwetsi bo: go tsewa 





How are you treated?  
English: Patient treatment depends on the severity of the condition or degree of the 
difficulty breathing. It ranges from admission in intensive care unit in critically ill 
patients with administration of intravenous drugs, oxygen and invasive cardiac 
monitoring to oral drugs in stable patients. 
Tswana: Tlhokomelo ya molwetsi e tla laolwa ke maemo a molwetsi jaaka go 
hupelwa, o ka okiwa mo bookelong kgotsa wa fiwa melimo go ikoka ko gae.  
 
What to expect?  
English: Most women recover normal heart function with treatment, 1 in 4 have 
persistent heart failure and 1 in 4 progressive deteriorate. 
Tswana: Bontsi jwa basadi bothata jwa pele bo a fola ka melemo, ke palo e ko tlase 




























Appendix G: MINNESOTA LIVING WITH HEART FAILURE QUESTIONNAIRE  
The following questions ask how much your heart failure (heart condition) affected 
your life during the past month (4 weeks). After each question, circle the 0, 1, 2, 3, 4 
or 5 to show how much your life was affected. If a question does not apply to you, 
circle the 0 after that question.  
Did your heart failure prevent you from living as you wanted during past 4 
months? 
________________________________________             No_ Very little  Too Much                                
1. Causing swelling in your ankles or legs?                             0    1    2     3     4      5       
2. making you sit or lie down to rest during the day?               0    1     2     3    4     5  
3. Making your walking about or climbing stairs difficult?        0    1     2    3     4      5  
4. Making your working around the house or yard difficult?     0    1     2    3     4    5  
5. making your going places away from home difficult?           0     1    2    3    4     5  
6. Making your sleeping well at night difficult?                          0    1    2    3    4     5  
7. Making your relating to or doing things with your friends or family difficult?  
                                                                                                   0   1   2     3     4     5  
8. Making your working to earn a living difficult?                        0     1   2    3    4     5  
9. Making your recreational pastimes, sports or hobbies difficult? 0  1  2   3    4     5  
10. Making your sexual activities difficult?                                    0   1   2   3    4     5  
11. Making you eat less of the foods you like?                             0   1     2    3    4    5  
12. Making you short of breath?                                                   0   1   2   3     4     5  
13. Making you tired, fatigued, or low on energy?                       0   1    2     3     4    5  
14. Making you stay in a hospital?                                              0    1    2   3    4     5  
15. Costing you money for medical care?                                  0    1   2    3    4    5  
80 
 
16. Giving you side effects from treatments?                             0    1    2   3    4    5  
17. Making you feel you are a burden to your family or friends?  0   1   2   3    4   5  
18. Making you feel a loss of self-control in your life?               0    1   2     3     4    5  
19. Making you worry?                                                                 0    1   2    3    4    5  
20. Making it difficult for you to concentrate or remember things? 0   1   2    3    4    5  




















Appendix H: Relationship of patient clinical outcome to risk factors 
Risk factor Number of 
patients 
affected (% )  
% Patients of 
variable who 
recovered 
% Patients of 
variable who 
remained stable 
% Patients of 
variable who 
deteriorated 
Neonatal mortality 4 (11.8) 25.0  75.0 
Not breastfeed 16 (47.1) 50.0 18.8 31.2 
Gestational HTN 20 (58.8) 35.0 30 35 
Pregnancy induced 
toxaemia (PET) 
17 (50) 35.3 29.4 35.3 
Vaginal delivery 23 (67.7) 56.6 21.7 21.7 
Caesarean section 11 (32.4) 27.2 36.4 36.4 
ICU Admission 6 (17.7) 33.3  66.7 
Inotropic support at 
diagnosis 
7 (21.0) 42.9  57.1 
HIV sero-positive 16 (47.1) 56.2 18.8 25 
Previous TB 5 (14.7) 20 20 60 
Mineralo-corticosteroid 
receptor inhibitor 
32 (94.1) 43.8 28.1 28.1 
Digoxin 11 (32.4) 27.3 27.3 45.46 
Anticoagulation 11 (32.4) 45.4 27.3 27.3 
Cough 32 (94.1) 43.8 25.00 31.2 
Tachypnoea 31 (91.1) 42.0 29.0 29.0 
Abnormal blood 
pressure 
17 (50) 47.1 11.8 41.1 
Elevated jugular 
venous pressure 
27 (79.4) 40.8 25.9 33.3 
Displaced apical 
impulse 
20 (58.8) 35.0 30.0 35.0 
Gallop rhythm 31 (91.1) 42.0 29.0 29.0 
Pedal oedema 32 (94.1) 43.8 28.1 28.1 
Basal crackles 31 (91.1) 48.4 25.8 25.8 
Stroke 2 (5.9)   100 
Pulmonary embolus 1 (2.9) 100   
Deep venous 
thrombus 
4 (11.8) 25 50 25 
Abnormal cardiac rate 33 (97.1) 45.4 27.3 27.3 
Sinus rhythm 32 (94.1) 46.9 25 28.1 
Bundle branch block 6 (17.7) 50 33.33 16.67 
Left ventricular 
hypertrophy 
15 (44.1) 33.3 26.7 40.00 
Right ventricular 
hypertrophy 
8 (23.5) 25 37.5 37.5 
Increased 
cardiothoracic ratio 
26 (76.5) 38.5 26.9 34.6 
Upper lobe diversion 31 (91.1) 51.6 25.8 22.6 
Kerley-B lines 21 (61.8) 52.4 19.0 28.6 
Alveolar infiltrates 29 (85.3) 41.4 27.6 31.0 
Pleural effusion 14 (41.2) 42.9 14.2 42.9 
 
Column 2 represents the number of patients who had the concerned risk factor, represented as a 
percentage of study participates in brackets. Columns 3, 4 and 5 shows the distribution of each risk 




Appendix I: Comparison means of proportions in different groups 
Tukey's Studentised Range (HSD) Test for Result 
 






Simultaneous 95% Confidence 
Limits 
  
Recovered - Deteriorated 5.051 -3.212 13.314   
Recovered - Stable 15.799 7.246 24.352 *** 
Deteriorated - Recovered -5.051 -13.314 3.212   
Deteriorated - Stable 10.748 2.195 19.301 *** 
Stable - Recovered -15.799 -24.352 -7.246 *** 
Stable - Deteriorated -10.748 -19.301 -2.195 *** 
 
 
